Chordia Therapeutics Inc. (190A.T) Latest Company News

Aug 26, 2026, 01:35 UTC
Chordia Therapeutics announced on August 25, 2026 that Japan's Ministry of Health, Labour and Welfare granted rare disease drug designation to its CLK inhibitor rogocekib for relapsed or refractory acute myeloid leukemia (AML).
Source:
- s.kabutan.jp
Aug 6, 2026, 09:26 UTC
Chordia Therapeutics announced that its collaborative research results on MALT1 with University of Miyazaki, Kyoto University, and National Cancer Center Japan were published in the journal iScience on July 23, 2026.
Source:
- s.kabutan.jp
Jul 22, 2026, 00:53 UTC
Chordia Therapeutics announced it has signed a subcontract research and development contract with Kyoto University and AMED under the 'Innovative Cancer Medical Practical Application Research Project', securing a grant of 0.3 billion yen for fiscal year 2027.
Source:
- s.kabutan.jp
Jul 17, 2026, 00:49 UTC
Chordia Therapeutics' rogocekib (CTX-712) advanced to an expansion cohort in its Phase 1/2 clinical trial for relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes.
Source:
- s.kabutan.jp
Jul 17, 2026, 00:49 UTC
Chordia Therapeutics terminated its license agreement with Ono Pharmaceutical for CTX-177 and regained all global rights.
Source:
- s.kabutan.jp
Jul 17, 2026, 00:49 UTC
Chordia Therapeutics reported its fiscal Q3 2026 results with no revenue, an operating loss of 1.070 billion yen, an ordinary loss of 1.046 billion yen, and a net loss of 1.047 billion yen.
Source:
- s.kabutan.jp
Jul 13, 2026, 02:22 UTC
Chordia Therapeutics published a research paper on the creation of novel scaffold compounds using AI, based on a study conducted in collaboration with Theoretical Drug Discovery Laboratory and Axcelead Drug Discovery Partners.
Source:
- s.kabutan.jp

190A.T

Chordia Therapeutics announced on August 25, 2026 that Japan's Ministry of Health, Labour and Welfare granted rare disease drug designation to its CLK inhibitor rogocekib for relapsed or refractory acute myeloid leukemia (AML).

Chordia Therapeutics announced that its collaborative research results on MALT1 with University of Miyazaki, Kyoto University, and National Cancer Center Japan were published in the journal iScience on July 23, 2026.

Chordia Therapeutics announced it has signed a subcontract research and development contract with Kyoto University and AMED under the 'Innovative Cancer Medical Practical Application Research Project', securing a grant of 0.3 billion yen for fiscal year 2027.

Chordia Therapeutics' rogocekib (CTX-712) advanced to an expansion cohort in its Phase 1/2 clinical trial for relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes.

Chordia Therapeutics terminated its license agreement with Ono Pharmaceutical for CTX-177 and regained all global rights.

Chordia Therapeutics reported its fiscal Q3 2026 results with no revenue, an operating loss of 1.070 billion yen, an ordinary loss of 1.046 billion yen, and a net loss of 1.047 billion yen.

Chordia Therapeutics published a research paper on the creation of novel scaffold compounds using AI, based on a study conducted in collaboration with Theoretical Drug Discovery Laboratory and Axcelead Drug Discovery Partners.